https://stock.noler.com/us/stock/pharmagen-inc https://stock.noler.com/us/stock/pharmagen-inc/accounts-payable https://stock.noler.com/us/stock/pharmagen-inc/accounts-payable-and-accrued-liabilities-current https://stock.noler.com/us/stock/pharmagen-inc/accounts-payable-and-other-accrued-liabilities-current https://stock.noler.com/us/stock/pharmagen-inc/accounts-payable-interest-bearing-interest-rate https://stock.noler.com/us/stock/pharmagen-inc/accounts-payable-related-parties-current https://stock.noler.com/us/stock/pharmagen-inc/accounts-receivable https://stock.noler.com/us/stock/pharmagen-inc/accretion-expense https://stock.noler.com/us/stock/pharmagen-inc/accretion-of-discount https://stock.noler.com/us/stock/pharmagen-inc/accrual-for-environmental-loss-contingencies https://stock.noler.com/us/stock/pharmagen-inc/accrued-liabilities-current https://stock.noler.com/us/stock/pharmagen-inc/accumulated-depreciation https://stock.noler.com/us/stock/pharmagen-inc/acquired-current-liabilities https://stock.noler.com/us/stock/pharmagen-inc/acquired-current-liabilities-long-term-debt https://stock.noler.com/us/stock/pharmagen-inc/acquired-current-liabilities-other https://stock.noler.com/us/stock/pharmagen-inc/acquired-finite-lived-intangible-asset-residual-value https://stock.noler.com/us/stock/pharmagen-inc/acquired-inventory https://stock.noler.com/us/stock/pharmagen-inc/acquired-net https://stock.noler.com/us/stock/pharmagen-inc/acquisition-acquired-receivables-gross-contractual-amount https://stock.noler.com/us/stock/pharmagen-inc/acquisition-recognized-identifiable-assets-acquired-goodwill-and-liabilities-assumed-less-noncontrolling-interest https://stock.noler.com/us/stock/pharmagen-inc/acquisition-recognized-identifiable-assets-acquired-goodwill-and-liabilities-assumed-net https://stock.noler.com/us/stock/pharmagen-inc/additional-paid-in-capital https://stock.noler.com/us/stock/pharmagen-inc/advertising-expense https://stock.noler.com/us/stock/pharmagen-inc/allowance-for-doubtful-accounts-receivable https://stock.noler.com/us/stock/pharmagen-inc/allowance-for-doubtful-accounts-receivable-current https://stock.noler.com/us/stock/pharmagen-inc/amortization-of-debt-discount-premium https://stock.noler.com/us/stock/pharmagen-inc/amortization-of-financing-costs https://stock.noler.com/us/stock/pharmagen-inc/antidilutive-securities-excluded-from-computation-of-earnings-per-share-amount https://stock.noler.com/us/stock/pharmagen-inc/assets-fair-value-disclosure https://stock.noler.com/us/stock/pharmagen-inc/business-acquisition-cost-of-acquired-entity-cash-paid https://stock.noler.com/us/stock/pharmagen-inc/business-acquisition-cost-of-acquired-entity-purchase-price https://stock.noler.com/us/stock/pharmagen-inc/business-acquisition-pro-forma-earnings-per-share-basic https://stock.noler.com/us/stock/pharmagen-inc/business-acquisition-purchase-price-allocation-assets-acquired https://stock.noler.com/us/stock/pharmagen-inc/business-acquisition-purchase-price-allocation-assets-acquired-liabilities-assumed-net https://stock.noler.com/us/stock/pharmagen-inc/business-acquisition-purchase-price-allocation-current-assets-inventory https://stock.noler.com/us/stock/pharmagen-inc/business-acquisition-purchase-price-allocation-current-assets-receivables https://stock.noler.com/us/stock/pharmagen-inc/business-acquisition-purchase-price-allocation-current-liabilities-accounts-payable https://stock.noler.com/us/stock/pharmagen-inc/business-acquisition-purchase-price-allocation-current-liabilities-other-liabilities https://stock.noler.com/us/stock/pharmagen-inc/business-acquisition-purchase-price-allocation-goodwill-amount https://stock.noler.com/us/stock/pharmagen-inc/business-acquisition-purchase-price-allocation-liabilities-assumed https://stock.noler.com/us/stock/pharmagen-inc/business-acquisition-purchase-price-allocation-notes-payable-and-long-term-debt https://stock.noler.com/us/stock/pharmagen-inc/business-acquisitions-pro-forma-net-income-loss https://stock.noler.com/us/stock/pharmagen-inc/business-acquisitions-pro-forma-revenue https://stock.noler.com/us/stock/pharmagen-inc/capital-expenditures https://stock.noler.com/us/stock/pharmagen-inc/capital-lease-obligations https://stock.noler.com/us/stock/pharmagen-inc/capital-lease-obligations-current https://stock.noler.com/us/stock/pharmagen-inc/capital-lease-obligations-noncurrent https://stock.noler.com/us/stock/pharmagen-inc/cash https://stock.noler.com/us/stock/pharmagen-inc/cash-and-equivalents https://stock.noler.com/us/stock/pharmagen-inc/cash-equivalents-at-carrying-value https://stock.noler.com/us/stock/pharmagen-inc/cash-flow-breakdown https://stock.noler.com/us/stock/pharmagen-inc/common-stock-par-or-stated-value-per-share https://stock.noler.com/us/stock/pharmagen-inc/common-stock-value https://stock.noler.com/us/stock/pharmagen-inc/conversion-of-stock-amount-issued https://stock.noler.com/us/stock/pharmagen-inc/convertible-debt https://stock.noler.com/us/stock/pharmagen-inc/convertible-debt-noncurrent https://stock.noler.com/us/stock/pharmagen-inc/convertible-notes-payable https://stock.noler.com/us/stock/pharmagen-inc/cost-of-goods-sold https://stock.noler.com/us/stock/pharmagen-inc/cost-of-real-estate-sales https://stock.noler.com/us/stock/pharmagen-inc/cover-page-shares-outstanding https://stock.noler.com/us/stock/pharmagen-inc/current-assets https://stock.noler.com/us/stock/pharmagen-inc/current-liabilities https://stock.noler.com/us/stock/pharmagen-inc/current-portion-of-long-term-debt https://stock.noler.com/us/stock/pharmagen-inc/debt-conversion-converted-instrument-amount https://stock.noler.com/us/stock/pharmagen-inc/debt-unamortized-discount https://stock.noler.com/us/stock/pharmagen-inc/debtor-reorganization-items-gain-loss-on-settlement-of-other-claims-net https://stock.noler.com/us/stock/pharmagen-inc/deferred-finance-cost-amortization-expense https://stock.noler.com/us/stock/pharmagen-inc/deferred-sales-inducements-amortization-expense https://stock.noler.com/us/stock/pharmagen-inc/deferred-tax-assets-gross https://stock.noler.com/us/stock/pharmagen-inc/deferred-tax-assets-liabilities-net https://stock.noler.com/us/stock/pharmagen-inc/deferred-tax-assets-net https://stock.noler.com/us/stock/pharmagen-inc/deferred-tax-assets-operating-loss-carryforwards https://stock.noler.com/us/stock/pharmagen-inc/deferred-tax-assets-valuation-allowance https://stock.noler.com/us/stock/pharmagen-inc/deposit-liabilities-accrued-interest https://stock.noler.com/us/stock/pharmagen-inc/depreciation https://stock.noler.com/us/stock/pharmagen-inc/depreciation-and-amortization-expense https://stock.noler.com/us/stock/pharmagen-inc/derivative-fair-value-of-derivative-liability https://stock.noler.com/us/stock/pharmagen-inc/derivative-fair-value-of-derivative-liability-amount-not-offset-against-collateral https://stock.noler.com/us/stock/pharmagen-inc/derivative-gain-loss-on-derivative-net https://stock.noler.com/us/stock/pharmagen-inc/derivative-gain-on-derivative https://stock.noler.com/us/stock/pharmagen-inc/derivative-liabilities https://stock.noler.com/us/stock/pharmagen-inc/derivative-liabilities-current https://stock.noler.com/us/stock/pharmagen-inc/derivative-liabilities-noncurrent https://stock.noler.com/us/stock/pharmagen-inc/derivative-liability-fair-value-net https://stock.noler.com/us/stock/pharmagen-inc/derivative-loss-on-derivative https://stock.noler.com/us/stock/pharmagen-inc/development-stage-enterprise-deficit-accumulated-during-development-stage https://stock.noler.com/us/stock/pharmagen-inc/due-to-officers-or-stockholders-current https://stock.noler.com/us/stock/pharmagen-inc/due-to-related-parties-current https://stock.noler.com/us/stock/pharmagen-inc/due-to-related-parties-current-and-noncurrent https://stock.noler.com/us/stock/pharmagen-inc/earnings-per-share-basic-and-diluted https://stock.noler.com/us/stock/pharmagen-inc/entity-wide-revenue-major-customer-percentage https://stock.noler.com/us/stock/pharmagen-inc/escrow-deposit https://stock.noler.com/us/stock/pharmagen-inc/fair-value-assumptions-expected-dividend-rate https://stock.noler.com/us/stock/pharmagen-inc/financing-cash-flow https://stock.noler.com/us/stock/pharmagen-inc/form-d-other https://stock.noler.com/us/stock/pharmagen-inc/form-d-stocks https://stock.noler.com/us/stock/pharmagen-inc/gain-loss-on-derivative-instruments-net-pretax https://stock.noler.com/us/stock/pharmagen-inc/gains-losses-on-extinguishment-of-debt https://stock.noler.com/us/stock/pharmagen-inc/general-and-administrative-expense https://stock.noler.com/us/stock/pharmagen-inc/goodwill https://stock.noler.com/us/stock/pharmagen-inc/goodwill-and-intangible-asset-impairment https://stock.noler.com/us/stock/pharmagen-inc/goodwill-fair-value-disclosure https://stock.noler.com/us/stock/pharmagen-inc/gross-profit https://stock.noler.com/us/stock/pharmagen-inc/impairment-of-intangible-assets-excluding-goodwill https://stock.noler.com/us/stock/pharmagen-inc/impairment-of-oil-and-gas-properties https://stock.noler.com/us/stock/pharmagen-inc/income-taxes-paid https://stock.noler.com/us/stock/pharmagen-inc/income-taxes-paid-2 https://stock.noler.com/us/stock/pharmagen-inc/increase-decrease-in-accounts-payable https://stock.noler.com/us/stock/pharmagen-inc/increase-decrease-in-accounts-payable-and-accrued-liabilities https://stock.noler.com/us/stock/pharmagen-inc/increase-decrease-in-accounts-receivable https://stock.noler.com/us/stock/pharmagen-inc/increase-decrease-in-accrued-liabilities https://stock.noler.com/us/stock/pharmagen-inc/increase-decrease-in-derivative-liabilities https://stock.noler.com/us/stock/pharmagen-inc/increase-decrease-in-due-to-related-parties-current https://stock.noler.com/us/stock/pharmagen-inc/increase-decrease-in-inventories https://stock.noler.com/us/stock/pharmagen-inc/increase-decrease-in-other-noncurrent-liabilities https://stock.noler.com/us/stock/pharmagen-inc/increase-decrease-in-prepaid-deferred-expense-and-other-assets https://stock.noler.com/us/stock/pharmagen-inc/insider-transactions-preferred https://stock.noler.com/us/stock/pharmagen-inc/insider-transactions-preferred/purchases https://stock.noler.com/us/stock/pharmagen-inc/insider-transactions-preferred/sales https://stock.noler.com/us/stock/pharmagen-inc/insider-transactions-warrants https://stock.noler.com/us/stock/pharmagen-inc/interest-and-debt-expense https://stock.noler.com/us/stock/pharmagen-inc/interest-expense https://stock.noler.com/us/stock/pharmagen-inc/interest-expense-related-party https://stock.noler.com/us/stock/pharmagen-inc/interest-paid https://stock.noler.com/us/stock/pharmagen-inc/interest-portion-of-minimum-lease-payments-sale-leaseback-transactions https://stock.noler.com/us/stock/pharmagen-inc/inventory https://stock.noler.com/us/stock/pharmagen-inc/inventory-finished-goods https://stock.noler.com/us/stock/pharmagen-inc/inventory-valuation-reserves https://stock.noler.com/us/stock/pharmagen-inc/investing-cash-flow https://stock.noler.com/us/stock/pharmagen-inc/issuance-of-stock-and-warrants-for-services-or-claims https://stock.noler.com/us/stock/pharmagen-inc/liabilities-fair-value-adjustment https://stock.noler.com/us/stock/pharmagen-inc/liability-for-uncertain-tax-positions-current https://stock.noler.com/us/stock/pharmagen-inc/line-of-credit-facility-amount-outstanding https://stock.noler.com/us/stock/pharmagen-inc/line-of-credit-facility-commitment-fee-amount https://stock.noler.com/us/stock/pharmagen-inc/line-of-credit-facility-interest-rate-at-period-end https://stock.noler.com/us/stock/pharmagen-inc/lines-of-credit-current https://stock.noler.com/us/stock/pharmagen-inc/litigation-settlement-amount https://stock.noler.com/us/stock/pharmagen-inc/litigation-settlement-gross https://stock.noler.com/us/stock/pharmagen-inc/long-term-debt-and-capital-lease-obligations https://stock.noler.com/us/stock/pharmagen-inc/minimum-lease-payments-sale-leaseback-transactions https://stock.noler.com/us/stock/pharmagen-inc/minimum-lease-payments-sale-leaseback-transactions-thereafter https://stock.noler.com/us/stock/pharmagen-inc/minimum-lease-payments-sale-leaseback-transactions-within-five-years https://stock.noler.com/us/stock/pharmagen-inc/minimum-lease-payments-sale-leaseback-transactions-within-four-years https://stock.noler.com/us/stock/pharmagen-inc/minimum-lease-payments-sale-leaseback-transactions-within-one-year https://stock.noler.com/us/stock/pharmagen-inc/minimum-lease-payments-sale-leaseback-transactions-within-three-years https://stock.noler.com/us/stock/pharmagen-inc/minimum-lease-payments-sale-leaseback-transactions-within-two-years https://stock.noler.com/us/stock/pharmagen-inc/net-change-in-cash https://stock.noler.com/us/stock/pharmagen-inc/net-income https://stock.noler.com/us/stock/pharmagen-inc/net-income-loss-attributable-to-noncontrolling-interest https://stock.noler.com/us/stock/pharmagen-inc/noncash-or-part-noncash-acquisition-other-liabilities-assumed https://stock.noler.com/us/stock/pharmagen-inc/noncash-or-part-noncash-acquisition-payables-assumed https://stock.noler.com/us/stock/pharmagen-inc/notes-payable-current https://stock.noler.com/us/stock/pharmagen-inc/operating-cash-flow https://stock.noler.com/us/stock/pharmagen-inc/operating-expenses https://stock.noler.com/us/stock/pharmagen-inc/operating-income https://stock.noler.com/us/stock/pharmagen-inc/operating-loss-carryforwards https://stock.noler.com/us/stock/pharmagen-inc/other-depreciation-and-amortization https://stock.noler.com/us/stock/pharmagen-inc/other-expenses https://stock.noler.com/us/stock/pharmagen-inc/other-income https://stock.noler.com/us/stock/pharmagen-inc/other-noncurrent-liabilities https://stock.noler.com/us/stock/pharmagen-inc/other-notes-payable https://stock.noler.com/us/stock/pharmagen-inc/payments-to-acquire-oil-and-gas-property https://stock.noler.com/us/stock/pharmagen-inc/preferred-shares-facts https://stock.noler.com/us/stock/pharmagen-inc/preferred-stock-par-or-stated-value-per-share https://stock.noler.com/us/stock/pharmagen-inc/preferred-stock-shares-authorized https://stock.noler.com/us/stock/pharmagen-inc/preferred-stock-shares-issued https://stock.noler.com/us/stock/pharmagen-inc/preferred-stock-shares-outstanding https://stock.noler.com/us/stock/pharmagen-inc/preferred-stock-value https://stock.noler.com/us/stock/pharmagen-inc/prepaid-expense-and-other-assets-current https://stock.noler.com/us/stock/pharmagen-inc/present-value-of-future-minimum-lease-payments-sale-leaseback-transactions https://stock.noler.com/us/stock/pharmagen-inc/proceeds-from-bank-debt https://stock.noler.com/us/stock/pharmagen-inc/proceeds-from-convertible-debt https://stock.noler.com/us/stock/pharmagen-inc/proceeds-from-issuance-of-convertible-preferred-stock https://stock.noler.com/us/stock/pharmagen-inc/proceeds-from-lines-of-credit https://stock.noler.com/us/stock/pharmagen-inc/proceeds-from-notes-payable https://stock.noler.com/us/stock/pharmagen-inc/proceeds-from-payments-for-long-term-loans-for-related-parties https://stock.noler.com/us/stock/pharmagen-inc/proceeds-from-related-party-debt https://stock.noler.com/us/stock/pharmagen-inc/proceeds-from-repayments-of-lines-of-credit https://stock.noler.com/us/stock/pharmagen-inc/proceeds-from-repayments-of-long-term-debt-and-capital-securities https://stock.noler.com/us/stock/pharmagen-inc/proceeds-from-repayments-of-related-party-debt https://stock.noler.com/us/stock/pharmagen-inc/proceeds-from-stock-issued https://stock.noler.com/us/stock/pharmagen-inc/professional-fees https://stock.noler.com/us/stock/pharmagen-inc/profit-loss https://stock.noler.com/us/stock/pharmagen-inc/property-plant-equipment https://stock.noler.com/us/stock/pharmagen-inc/public-float https://stock.noler.com/us/stock/pharmagen-inc/purchase-obligation https://stock.noler.com/us/stock/pharmagen-inc/purchase-obligation-due-in-fifth-year https://stock.noler.com/us/stock/pharmagen-inc/purchase-obligation-due-in-fourth-year https://stock.noler.com/us/stock/pharmagen-inc/purchase-obligation-due-in-next-twelve-months https://stock.noler.com/us/stock/pharmagen-inc/purchase-obligation-due-in-second-year https://stock.noler.com/us/stock/pharmagen-inc/purchase-obligation-due-in-third-year https://stock.noler.com/us/stock/pharmagen-inc/receivable https://stock.noler.com/us/stock/pharmagen-inc/related-party-transaction-due-from-to-related-party https://stock.noler.com/us/stock/pharmagen-inc/related-party-transaction-other-revenues-from-transactions-with-related-party https://stock.noler.com/us/stock/pharmagen-inc/repayments-of-lines-of-credit https://stock.noler.com/us/stock/pharmagen-inc/repayments-of-notes-payable https://stock.noler.com/us/stock/pharmagen-inc/results-of-operations-income-before-income-taxes https://stock.noler.com/us/stock/pharmagen-inc/retained-earnings https://stock.noler.com/us/stock/pharmagen-inc/revenue https://stock.noler.com/us/stock/pharmagen-inc/revenue-from-related-parties https://stock.noler.com/us/stock/pharmagen-inc/salaries-and-wages https://stock.noler.com/us/stock/pharmagen-inc/sales-revenue-goods-gross https://stock.noler.com/us/stock/pharmagen-inc/sales-revenue-goods-net https://stock.noler.com/us/stock/pharmagen-inc/sales-revenue-net https://stock.noler.com/us/stock/pharmagen-inc/shareholders-equity https://stock.noler.com/us/stock/pharmagen-inc/shares-authorized https://stock.noler.com/us/stock/pharmagen-inc/shares-issued https://stock.noler.com/us/stock/pharmagen-inc/shares-issued-shares-issued-for-services https://stock.noler.com/us/stock/pharmagen-inc/stock-issued-shares-issued-value-issued-for-services https://stock.noler.com/us/stock/pharmagen-inc/stock-issued-shares-issued-value-other https://stock.noler.com/us/stock/pharmagen-inc/total-assets https://stock.noler.com/us/stock/pharmagen-inc/total-liabilities https://stock.noler.com/us/stock/pharmagen-inc/total-liabilities-and-equity https://stock.noler.com/us/stock/pharmagen-inc/valuation-allowance-amount https://stock.noler.com/us/stock/pharmagen-inc/weighted-average-basic-shares-outstanding-pro-forma https://stock.noler.com/us/stock/pharmagen-inc/weighted-average-number-of-share-outstanding-basic-and-diluted